Growth hormone response to growth hormone releasing hormone 1-40 in Turner's syndrome

Horm Res. 1987;27(1):1-6. doi: 10.1159/000180770.

Abstract

The response of growth hormone (GH) to acute administration of GH-releasing hormone 1-40 (GHRH) was evaluated in 12 patients with Turner's syndrome and in 12 prepubertal or early pubertal girls. In 7 of 12 patients GHRH induced a definite increase (greater than 10 ng/ml) of plasma GH levels. In 5 patients there was a poor GH rise after GHRH administration (less than 10 ng/ml). Overall, the mean GH response of patients was significantly lower than that of normal girls. Five out of 7 patients with a 45 X,O karyotype had a reduced GH rise after GHRH, while all patients with non X,O karyotype (mosaicism and/or 46 X,iX) had a normal GH response to GHRH. Although the cause of short stature in patients with Turner's syndrome is most likely multifactorial, a reduced pituitary GH reserve, as documented by the reduced GH response to GHRH in some of our patients, may contribute to the growth impairment in this disorder.

MeSH terms

  • Adolescent
  • Adult
  • Clonidine / therapeutic use
  • Female
  • Growth Hormone / blood
  • Growth Hormone-Releasing Hormone / therapeutic use*
  • Humans
  • Levodopa / therapeutic use
  • Peptide Fragments / therapeutic use*
  • Turner Syndrome / drug therapy*

Substances

  • Peptide Fragments
  • somatotropin releasing factor 40
  • Levodopa
  • Growth Hormone
  • Growth Hormone-Releasing Hormone
  • Clonidine